Skip to main content

SCIg vs. IVIg: let’s give patients the choice!


Criteria governing the choice between intravenous (IV) and subcutaneous (SC) routes for immunoglobulin (Ig) substitution are not well defined. We assessed the consequences of giving the choice to the patient.


We retrospectively analyzed 143 patients with primary immunodeficiency, followed in a single center, which were offered the choice of IVIg or SCIg. We analyzed the route more frequently chosen, and the consequences on compliance. In a first cohort (n = 51, average follow up 52 months), patients already on IVIg were offered the choice to stay on IVIg or to switch to SCIg (switch cohort). In a second cohort (n = 92, average follow up 11 months), newly diagnosed patients were offered the choice between IVIg and SCIg before the first injection (new cohort).


In the switch cohort, 50/51 patients chose to switch to SCIg. Of these, 90% remained on SCIg. In the new cohort, 44/92 patients chose SCIg, of which 95% remained on SCIg. Among the 48 patients who chose IVIg, 73% switched to SCIg. Compliance issues were observed in only 10 patients.


Giving patients the choice of treatment modality is a safe strategy in terms of compliance. Home-based SCIg is much more frequently chosen than hospital-based IVIg. Given the equal efficacy and safety between hospital-based IVIg and home-based SCIg, we believe that all patients should be given the choice regardless of physician’s belief of “idealness” of the candidate.

Author information



Corresponding author

Correspondence to Elie Haddad.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Samaan, K.K., Levasseur, MC.R., Decaluwe, H. et al. SCIg vs. IVIg: let’s give patients the choice!. All Asth Clin Immun 10, A13 (2014).

Download citation


  • Public Health
  • Treatment Modality
  • Single Center
  • Primary Immunodeficiency
  • Equal Efficacy